Clairvee® CLINICAL TRIALS

The clinical evidence behind Clairvee®

Clairvee is a vaginal pre+probiotic formulated to relieve vaginal odor, itching and discharge. Below is a summary of the clinical evidence supporting its efficacy. 


  • 4 clinical studies & 1 online survey
  • Includes randomized, double-blind placebo controlled trial
  • Presented at the annual menopause society
  • Peer-reviewed & published in indexed journals

Clairvee has been evaluated in four clinical studies involving women with vaginal odor, discharge and microbiome imbalance. The results of these studies have been published in peer-review journals, with one being presented at The Menopause Society's annual meeting.

Bonafide requires clinical testing for most products. This approach gives both our customers and healthcare providers confidence that our products are safe and effective and that our claims are supported by rigorous evidence. 

Clairvee® TRIAL 1

Clairvee relieved vaginal discharge and itching in 15 days

In 15 days, participants experienced relief from vaginal discharge and itching in patients without an infection or culture (nugent score 4-6), compared to placebo.

Russo R, Edu A, De Seta F. Arch Gynecol Obstet. 2018; 298(1):139-145

FIND THE STUDYOpens in a new window.
  • RCT

    randomized, double-blind, placebo-controlled trial

  • 40 women

    study size

  • 15 days

    time to relief

Clairvee® TRIAL 2

100% of women with moderate to severe odor experienced relief after 6 months

In an open-label trial of women with vaginal odor and no known vaginal infection, Clairvee® relieved vaginal odor in just two weeks, and provided continued relief over six months. After six months, the majority of women reported that their odor was completely eliminated.*

*Includes women who reported their odor as “moderate” at baseline and “absent” after 6 months using Clairvee. After 6 months, 54% said their odor was completely eliminated.

Results from an open-label clinical study - interim data presented at the Menopause Society 2022 Annual Meeting. Full 6-month data on file

  • Open label

    open-label clinical trial

  • 48 women

    study size

  • 100%

    of women experienced relief

  • Published

    in the Menopause Journal

Clairvee® TRIAL 3

83% of women maintained a balanced vaginal microbiome at 6 months

After taking Clairvee for six months, 83% of women maintained a balanced vaginal microbiome, vs. only 21% in the placebo group (p<0.001).

Russo R, Karadja E, De Seta F. Beneficial Microbes. 2019;10(1): 19-26.

FIND THE STUDYOpens in a new window.
  • RCT

    randomized, double-blind, placebo-controlled trial

  • 48 women

    study size

  • 83%

    of women maintained a balanced vaginal microbiome

  • Published

    in Beneficial Microbes

Learn more about Clairvee

See the full product page, ingredients, and how to get started.

SHOP CLAIRVEE